On July 26, 2023, Professor Song Guangyuan, the Director of the Heart Valve Intervention Center at Beijing Anzhen Hospital, Capital Medical University, successfully completed the first day enrollment with his team using the TaurusTrioTM Transcatheter Aortic Valve Replacement (“TAVR”) system via the femoral artery. On the first day, they enrolled 5 cases. All the cases on the first day were patients with severe aortic regurgitation (“AR”) who were not suitable for conventional surgical procedures. The procedures went smoothly, and the artificial valve implantation was in an ideal position with a good morphology. Immediately after the procedure, aortic valve regurgitation disappeared. The average procedural time was over 20 minutes, with the fastest procedural time being only 10 minutes. This validates the safety and ease of use of TaurusTrioTM when following standardized procedures.
The successful completion of these procedures marks the initiation of enrollment for the TaurusTrioTM treatment of AR in a multi-center clinical trial in China. It also signifies an important milestone in the collaboration between the JenaValve Technology Inc., the pioneer and owner of the positioning key patent, and Peijia Medical after their License-in partnership was established in China. This achievement is expected to lead and accelerate the new era of TAVR treatment for AR in China.
